Ibio Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.28
- Today's High:
- $0.335
- Open Price:
- $0.2835
- 52W Low:
- $0.26
- 52W High:
- $16.51
- Prev. Close:
- $0.28
- Volume:
- 959485
Company Statistics
- Market Cap.:
- $6.33 million
- Book Value:
- 1.099
- Revenue TTM:
- $499000
- Operating Margin TTM:
- -10873.55%
- Gross Profit TTM:
- $2.17 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -42.46%
- Return on Equity TTM:
- -114.82%
Company Profile
Ibio Inc had its IPO on 2008-08-19 under the ticker symbol IBIO.
The company operates in the Healthcare sector and Biotechnology industry. Ibio Inc has a staff strength of 105 employees.
Stock update
Shares of Ibio Inc opened at $0.28 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.28 - $0.34, and closed at $0.32.
This is a +14.29% increase from the previous day's closing price.
A total volume of 959,485 shares were traded at the close of the day’s session.
In the last one week, shares of Ibio Inc have increased by +10.34%.
Ibio Inc's Key Ratios
Ibio Inc has a market cap of $6.33 million, indicating a price to book ratio of 0.1024 and a price to sales ratio of 1.7708.
In the last 12-months Ibio Inc’s revenue was $499000 with a gross profit of $2.17 million and an EBITDA of $-50825000. The EBITDA ratio measures Ibio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ibio Inc’s operating margin was -10873.55% while its return on assets stood at -42.46% with a return of equity of -114.82%.
In Q1, Ibio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 87.6%.
Ibio Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-139.61 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ibio Inc’s profitability.
Ibio Inc stock is trading at a EV to sales ratio of 6.1547 and a EV to EBITDA ratio of -0.2958. Its price to sales ratio in the trailing 12-months stood at 1.7708.
Ibio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $44.39 million
- Total Liabilities
- $22.28 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $201000
- Dividend Payout Ratio
- 0%
Ibio Inc ended 2024 with $44.39 million in total assets and $0 in total liabilities. Its intangible assets were valued at $44.39 million while shareholder equity stood at $17.39 million.
Ibio Inc ended 2024 with $0 in deferred long-term liabilities, $22.28 million in other current liabilities, 16000.00 in common stock, $-282907000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.56 million and cash and short-term investments were $6.56 million. The company’s total short-term debt was $14,342,000 while long-term debt stood at $0.
Ibio Inc’s total current assets stands at $27.09 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $1.24 million compared to accounts payable of $2.01 million and inventory worth $18.37 million.
In 2024, Ibio Inc's operating cash flow was $0 while its capital expenditure stood at $201000.
Comparatively, Ibio Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.32
- 52-Week High
- $16.51
- 52-Week Low
- $0.26
- Analyst Target Price
- $1
Ibio Inc stock is currently trading at $0.32 per share. It touched a 52-week high of $16.51 and a 52-week low of $16.51. Analysts tracking the stock have a 12-month average target price of $1.
Its 50-day moving average was $0.46 and 200-day moving average was $0.92 The short ratio stood at 0.38 indicating a short percent outstanding of 0%.
Around 220.2% of the company’s stock are held by insiders while 1080.9% are held by institutions.
Frequently Asked Questions About Ibio Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc, as well as a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company’s AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.